Claim OwnershipOncology Brothers: Practice-Changing Cancer Discussions
Subscribed: 11Played: 119
Subscribe
© Oncology Brothers
Description
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
75 Episodes
Reverse
In this episode of the Oncology Brothers podcast, join Drs. Rahul and Rohit Gosain as they delve into the world of localized treatment options for gastrointestinal malignancies. They are joined by experts in the field, Drs. Nina Sanford, Jeffrey Ryckman, and Harris Chengazi, who provide insights into radiation oncology and interventional radiology modalities for treating liver cancer.
The discussion covers the basics of radiation oncology terminology, including SRS, SBRT, and proton therapy, and how these modalities have evolved over the last decade. The experts also discuss the various tools available in the interventional radiology toolkit, such as ablation techniques, chemoembolization, and radioembolization.
Listeners gain valuable insights into the considerations for referring patients with liver-confined hepatocellular carcinoma to radiation oncologists or interventional radiologists, depending on the size of the tumor and underlying liver function. The experts emphasize the importance of a multidisciplinary approach in cancer care to ensure the best treatment outcomes for patients.
Tune in to learn about the side effects of SBRT, the nuances of combining different treatment modalities, and the significance of collaboration among oncology specialists. This episode highlights the importance of understanding and appreciating the diverse treatment options available for cancer patients.
Don't miss out on this informative discussion on localized treatment options for gastrointestinal malignancies with the Oncology Brothers podcast.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Welcome back to another informative episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Caitlin Costello, an associate professor specializing in multiple myeloma at UC San Diego. Together, they delve into the evolving landscape of newly diagnosed multiple myeloma, covering essential topics such as diagnostic workup, treatment paradigms, and the role of minimal residual disease (MRD) in monitoring response.
Dr. Costello provides valuable insights into the minimal workup required before initiating treatment for multiple myeloma, emphasizing the importance of advanced imaging techniques and specific biomarkers for risk assessment. The discussion also touches on tailored treatment approaches for transplant-eligible and transplant-ineligible patients, as well as maintenance therapy considerations based on risk profiles.
Throughout the episode, key points such as the use of quadruplet therapy, the significance of MRD negativity, and strategies for managing high-risk patients are explored in detail. Dr. Costello also shares practical tips for community oncologists managing multiple myeloma patients, including the importance of biomarker monitoring and prophylactic measures.
Don't miss this insightful conversation that sheds light on the latest advancements in multiple myeloma care. Stay informed and up-to-date with the Oncology Brothers podcast as they continue to provide valuable insights for oncology professionals. Subscribe now to stay connected with the latest developments in hematology oncology!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In this informative podcast episode, the Oncology Brothers delve into the world of hematologic malignancies, focusing specifically on Chronic Lymphocytic Leukemia (CLL). Dr. Nitin Jain from MD Anderson Cancer Center joins the discussion, sharing insights on the latest treatment options and guidelines for CLL.
The episode covers essential topics such as determining when a patient with CLL needs treatment, the minimal workup required for scans and biopsies, and the decision-making process between time-limited venetoclax and long-term BTK inhibitors. Dr. Jain also discusses the use of second-generation BTK inhibitors like Acalabrutinib and Zanabrutinib, as well as the recent approvals of Partibrutinib and CAR-T for third-line treatment.
Tune in to gain a deeper understanding of CLL treatment strategies, managing side effects, and the evolving landscape of hematologic malignancies. Don't miss out on this insightful conversation that will benefit both healthcare professionals and patients navigating CLL treatment options.
Stay informed and stay tuned for upcoming episodes on multiple myeloma and myelofibrosis with the Oncology Brothers. Subscribe now to stay updated on the latest in oncology care.
Join us for yet another episode of The Oncology Brothers podcast, where we delve into the FRESCO2 study in metastatic colorectal cancer. In this episode, we are joined by Dr. Arvind Dasari from MD Anderson, the lead author of the study, to discuss the approval of fruquintinib and its impact on refractory colorectal cancer patients.
Discover how fruquintinib has significantly improved progression-free and overall survival, providing a new treatment option for patients who have exhausted other therapies. Dr. Dasari shares insights on the study design, results, and the practical implications of incorporating fruquintinib into clinical practice.
Tune in to learn about the key findings, side effects, dosing strategies, and real-world experiences with fruquintinib in managing refractory colorectal cancer. Take advantage of this informative episode that sheds light on the evolving landscape of colon cancer treatments. Subscribe to The Oncology Brothers podcast for more insightful discussions on cancer care. #Oncology #ColorectalCancer #FRESCO2Study
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Sam Klempner, a medical oncologist specializing in upper GI malignancies. Together, they delve into the current treatment strategies for esophageal, GE junction, and gastric adenocarcinoma.
The discussion covers a range of topics, including the evolving paradigms in neoadjuvant and adjuvant therapies, the importance of biomarker testing such as MSI and PD-L1, and the potential impact of new targets like Claudin 18.2 in upper GI cancers. Dr. Klempner also shares insights on the management of metastatic disease, including the role of targeted therapies like TDXD and Zolbetuximab.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the current landscape of upper GI malignancies. Stay informed and join the Oncology Brothers as they navigate the complexities of treating these challenging cancers. Don't miss out on this informative discussion!
Tune in to the Oncology Brothers podcast for more expert insights and discussions on oncology topics. Remember to like, share, and subscribe for more content on the latest developments in cancer care. Thank you for listening!
In this episode of Oncology Brothers, join hosts Drs. Rahul and Rohit as they dive into the management of colon cancer with special guest Dr. Aparna Parikh, a medical oncologist from Mass General Hospital. Dr. Parikh shares insights on the treatment algorithm for colon cancer, including the use of circulating tumor DNA and the latest advancements in treatment options. From localized disease to metastatic space, the discussion covers key aspects of managing colon cancer. Tune in to learn about the evolving landscape of colon cancer treatment and the importance of personalized patient-centered care. Don't miss out on this informative episode with the Oncology Brothers and Dr. Aparna Parikh!
Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, in this engaging podcast episode as they delve into the treatment landscape for hepatocellular carcinoma (HCC) with Dr. Tanios S. Bekaii-saab from Mayo Clinic. The discussion covers the treatment options for different stages of HCC, including liver transplant, local therapy, and systemic treatments. Dr. Tanios S. Bekaii-saab provides insights on utilizing Atezolizumab with Bevacizumab, dual checkpoint inhibitors, and TKIs in advanced or metastatic HCC. Clinical pearls on managing side effects and patient selection criteria are also discussed. Don't miss this comprehensive overview of HCC treatment strategies in both community and academic settings. Stay informed and educated on the latest developments in oncology with the Oncology Brothers podcast series. Subscribe now for more insightful discussions on various cancer types and treatment approaches. #Oncology #HepatocellularCarcinoma #CancerTreatment #PodcastEpisode
Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, as they dive deep into the groundbreaking EV302 study with special guest Dr. Thomas Powles. In this episode, they discuss the approval of Enfortumab and Pembrolizumab as a combination therapy for advanced bladder cancer, based on the remarkable results of the study. Dr. Powles shares insights on the study design, findings, and the transformative impact of the treatment on patients' lives. Discover how this new standard of care in bladder cancer has significantly improved overall survival benefits, with a median survival of 31.5 months compared to 16.1 months with chemotherapy. The discussion also delves into managing the side effects of the treatment and the potential use of ctDNA in monitoring disease progression. Don't miss this informative episode that sheds light on the evolving landscape of bladder cancer treatment and the hope it brings to patients. Stay tuned for a quick recap and insights from the Oncology Brothers.
Bladder Cancer Treatment Options: A Comprehensive Discussion | Oncology Brothers Podcast
Join the Oncology Brothers, Rahul Gosain and Rohit Gosain, in this insightful podcast episode where they are joined by Dr. Karine Tawagi, a medical oncologist, and Dr. Sia Daneshmand, a urologist, to discuss the current standard of care and treatment options for bladder cancer. In this episode, the experts delve into the treatment approaches for non-muscle invasive bladder cancer, including the use of BCG, pembrolizumab, and other emerging therapies. They also cover the management of muscle invasive bladder cancer, highlighting the role of neoadjuvant chemotherapy, cystectomy, and immunotherapy. The conversation extends to metastatic bladder cancer, focusing on the groundbreaking EV Pembro treatment and the evolving landscape of treatment options post-progression. The experts provide valuable insights into managing toxicities associated with different therapies and offer clinical pearls for healthcare providers. Don't miss this informative discussion on bladder cancer treatment options, featuring expert insights and practical recommendations for healthcare professionals. Tune in to the Oncology Brothers Podcast now! Listen to the full episode here. Stay informed and updated on the latest advancements in oncology with the Oncology Brothers podcast series. Subscribe now for more engaging discussions and expert insights.
#Bladder #Cancer #Treatment #Algorithm
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In this episode joined by Dr. Monty Pal from City of Hope to discuss the latest advancements in the treatment of renal cell cancer. The conversation covers topics such as adjuvant pembrolizumab, personalized medicine, second-line treatment options, and the role of TKIs and immune checkpoint inhibitors. Dr. Pal shares insights on clinical pearls, treatment algorithms, and ongoing clinical trials in the field. Tune in to stay informed about the current standard of care practices in renal cell cancer treatment.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In discussion with Dr. Rana McKay, Associate Professor of Medicine from UC San Diego Health, we covered the treatment algorithm for Prostate cancer, starting from localized disease and then focusing on CSPC and CRPC.
#Prostate #Cancer #Cancer #2024 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In this discussion with Dr. Hope Rugo, we covered her study Capitello-291, which led to the approval of Capivasertib in hormone receptor-positive breast cancer with AKT1, PTEN, and PIK3CA mutations, which are seen in 40-50% of the cases. We touched base on sequencing of this therapy, and important clinical pearls around the side effect management associated with this drug.
In discussion with Dr. Virginia Kaklamani, we cover treatment algorithm of HR+ breast cancer. We covered the current standard of care treatment options for HR+ breast cancer.
#HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In discussion with Dr. Tian Zhang, covering the Genitourinary ASCO 2024 meeting highlights from the Community Oncology perspective. We covered 4 important practice informing studies from GU ASCO with Dr. Zhang:
- CONTACT-02: Phase 3 study of cabozantinib plus atezolizumab vs second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer
- BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer bearing homologous recombination-repair mutations
- AMBASSADOR: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma vs observation
- Keynote-564: Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma
In discussion with Dr. Harold Burstein, we cover treatment algorithm of HER2+ breast cancer. We covered the current standard of care treatment options for HER2+ breast cancer.
#HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In discussion with Dr. Pamela Kunz, covering the Gastroenterology ASCO 2024 meeting highlights from Community Oncology perspective. We covered 3 important practice informing studies from GI ASCO with Dr. Kunz:
- CheckMate 8HW: Nivolumab plus ipilimumab vs chemotherapy as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer
- EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization
- NETTER-2: [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors
Discussing the management using the algorithm of Triple Negative Breast Cancer (TNBC) - with Dr. Ruth O'Regan Chair of medicine Charles A. Dewey Professor at the University of Rochester Wilmot Cancer Institute & Dr. Anna Weiss Associate Professor - Department of Surgery, Oncology Wilmot Cancer Institute.
In discussion with Dr. Uma Borate from the Ohio State University Comprehensive Cancer Center, The James, covering the leukemia, myelofibrosis and myelodysplastic syndrome key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Borate:
- TRANSFORM-1: Ph III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, International, Study of Navitoclax in Combination with Ruxolitinib vs Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis
- MANIFEST-2: Ph III, Randomized, Double-Blind Study, Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis
- SAVE: Phase I/II, Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in AML
- AUGMENT-101: Ph I/II, Revumenib Monotherapy in Patients with R/R KMT2Ar Acute Leukemias: Efficacy and Safety Results
#ASH #Leukemia #MDS #Myelofibrosis #Blood #Cancer #2023 #oncology #oncbrothers
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
In discussion with Dr. Daniel G. Stover, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 3 important practice informing studies in HER2+ disease with Dr. Stover:
- APHINITY Sub-analysis: Benefit of Adj Pertuzumab and Trastuzumab According to ER and HER2 Expression
- KATHERINE Update: Phase III Study of Adjuvant TDM-1 vs Trastuzumab for Residual Invasive HER2-positive Early Breast Cancer After Neoadj Chemo: Final IDFS and Updated OS analysis
- HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and TDM1 for Previously Treated HER2-positive Metastatic Breast Cancer
In discussion with Dr. Hope Rugo, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Rugo:
- NATALEE Update – Ribociclib + Nonsteroidal AI as Adj Treatment in Patients with HR+/HER2− Early Breast Cancer: Final iDFS analysis
- MONARCH 3 – Final OS Results of Abemaciclib Plus a Nonsteroidal AI as First-line Therapy for HR+, HER2– Advanced Breast Cancer
- INAVO120 – Phase III Study of Inavolisib or Placebo in Combination with Palbociclib and Fulvestrant in Patients with PIK3CA-mut, HR+, HER2– Locally Adv/Metastatic Breast Cancer
- TROPION-Breast01 – Phase III Study of Dato-DXd vs Chemo for Patients with Previously Treated Inoperable/Metastatic HR+, HER2– Breast Cancer
Comments
Download from Google Play
Download from App Store
United States